-+ 0.00%
-+ 0.00%
-+ 0.00%

Eli Lilly fell 0.2% in early Thursday trading. The company agreed to acquire Ventyx Biosciences in an all-cash deal to expand its line of oral small molecule therapies for chronic inflammation in multiple diseases.

Zhitongcaijing·01/08/2026 15:49:07
Listen to the news
Eli Lilly fell 0.2% in early Thursday trading. The company agreed to acquire Ventyx Biosciences in an all-cash deal to expand its line of oral small molecule therapies for chronic inflammation in multiple diseases.